Screening of tumor-targeting peptides for diagnosis and therapy through phage display technology
Received:February 02, 2021  Revised:March 24, 2021
View Full Text  View/Add Comment  Download reader
DOI:10.46701/BG.2021012021103
KeyWord:tumor-targeting peptide  phage display technology  diagnosis  drug discovery
                 
AuthorInstitution
Zhiruo Song Department of Pathogen Biology, Nanjing Medical University, Nanjing, Jiangsu 211166, China
Yufeng Zhang Department of Pathogen Biology, Nanjing Medical University, Nanjing, Jiangsu 211166, China
Yuanjie Zhu Department of Pathogen Biology, Nanjing Medical University, Nanjing, Jiangsu 211166, China;Key Laboratory of Antibody Techniques of National Health Commission, Nanjing Medical University, Nanjing, Jiangsu 211166, China
Mingming Zhang Key Laboratory of Antibody Techniques of National Health Commission, Nanjing Medical University, Nanjing, Jiangsu 211166, China
Xinjian Liu Department of Pathogen Biology, Nanjing Medical University, Nanjing, Jiangsu 211166, China;Key Laboratory of Antibody Techniques of National Health Commission, Nanjing Medical University, Nanjing, Jiangsu 211166, China
Minjun Ji Department of Pathogen Biology, Nanjing Medical University, Nanjing, Jiangsu 211166, China
Hits: 2490
Download times: 3013
Abstract:
      Phage display technology was introduced by G. Smith in 1985, which is highly effective in the selection of affinity peptides from a library containing billions of display peptides. The obtained peptides show potential efficacy in the development of further clinical applications, especially in tumor treatment. In this review, the basic principles, limits, developments of phage display technology and peptide libraries are introduced. Following that, the amino acid sequence of tumor target peptides for hematological and other systems are discussed. Finally, the application of target peptides in the design of imaging probes and the development of target peptide drugs for diagnosis and therapy are noted.
Close